Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced a new 7-robot contract with a publicly traded biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. The new client subscribed to one K5 ASR assigned to patrol a 4-story garage and six K1-Tower ASRs to monitor building entrances, open areas and parking lots throughout the corporate campus.
The announcement reads, “A secure and resilient pharmaceutical supply chain in the United States is the best means to ensure that U.S. patients and the health care system have access to a consistent and dependable supply of critical medicines. At the top of the supply chain are the pharmaceutical corporate campuses that require a robust, multi-layered safety and security program similar to the one described in a recent Knightscope blog. And according to the National Institutes of Health (‘NIH’), protecting the integrity of that supply chain is critical to providing medications that are free from adulteration (counterfeit, substandard or unapproved medications), making them safe for patient use. Knightscope’s technologies will help safeguard the material and intellectual property under development at this cutting-edge facility as well as the staff who are assisting people lead healthier lives.”
To view the full press release, visit https://ibn.fm/hf9SM
About Knightscope, Inc.
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN